Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -79,979 | -98,792 | -157,044 | -125,752 | -59,456 |
| Depreciation Amortization | N/A | N/A | N/A | 1 | 4 |
| Accounts receivable | N/A | 512 | -512 | N/A | N/A |
| Accounts payable and accrued liabilities | 625 | -1,756 | 421 | 2,846 | 7,824 |
| Other Working Capital | -1,579 | 3,080 | 10,593 | -7,865 | 10,850 |
| Other Operating Activity | 29,178 | 45,296 | 42,740 | 38,896 | 12,970 |
| Operating Cash Flow | $-51,756 | $-51,659 | $-103,802 | $-91,873 | $-27,809 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 51,562 | 50,453 | 19,734 | -54,118 | -34,448 |
| Investing Cash Flow | $51,562 | $50,453 | $19,734 | $-54,118 | $-34,448 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 247 | N/A | 44,697 | 187,940 | 28,584 |
| Other Financing Activity | -287 | -99 | 324 | 0 | -110 |
| Financing Cash Flow | $-40 | $-99 | $45,021 | $187,940 | $28,473 |
| Beginning Cash Position | 4,092 | 5,396 | 44,443 | 2,495 | 36,279 |
| End Cash Position | 3,857 | 4,092 | 5,396 | 44,443 | 2,495 |
| Net Cash Flow | $-235 | $-1,304 | $-39,048 | $41,948 | $-33,783 |
| Free Cash Flow | |||||
| Operating Cash Flow | -51,756 | -51,659 | -103,802 | -91,873 | -27,809 |
| Free Cash Flow | -51,756 | -51,659 | -103,802 | -91,873 | -27,809 |